Only 13 spots left

~13 spots leftby Oct 2027

CUE-101 for Throat Cancer

Recruiting in Palo Alto (17 mi)

Overseen byDouglas R. Adkins

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Recruiting

Sponsor: Washington University School of Medicine

Must not be taking: Corticosteroids, Immunosuppressants

Disqualifiers: Transplant history, Metastases, Cardiovascular disease, others

Stay on Your Current Meds

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This trial tests a new treatment called CUE-101 to see if it is safe and effective for patients with a specific type of throat cancer. The treatment aims to boost the immune system before standard cancer therapy. Patients are newly diagnosed and have not yet received any other treatments.

Do I need to stop my current medications to join the trial?

The trial does not specify if you need to stop taking your current medications. However, you cannot participate if you have been treated with corticosteroids (more than 10 mg per day prednisone or equivalent) or other immune suppressive drugs within 14 days before starting the study drug.

Research Team

Douglas R. Adkins

Principal Investigator

Washington University School of Medicine

Eligibility Criteria

This trial is for adults with newly diagnosed, locally advanced HPV16+ oropharyngeal squamous-cell carcinoma who are HLA-A*0201 positive. They should be able to undergo standard cancer treatments and have a good performance status (ECOG ≤ 1). Patients must not have had previous head and neck radiation, other cancers in the last two years (with some exceptions), or certain health conditions like uncontrolled hypertension or recent heart attacks.

Inclusion Criteria

My cancer is confirmed to be squamous-cell carcinoma in the throat or upper neck.

My cancer is stage I-III, but not the earliest stages of T1N0 or T2N0.

My tumor is HPV16 positive and shows high p16 protein levels.

See 8 more

Exclusion Criteria

I have had radiation therapy on my head or neck before.

I have a history of hepatitis B or C but have been in remission for over a year if treated.

History of prior allogeneic bone marrow, stem-cell or solid organ transplantation

See 13 more

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Neoadjuvant Treatment

CUE-101 is administered in one of three schedules before standard of care therapy

2 weeks

Multiple visits for CUE-101 administration and assessments

Standard of Care Therapy

Participants undergo surgery and/or chemoradiation therapy as per standard of care

Varies based on treatment plan

Follow-up

Participants are monitored for safety and effectiveness after treatment

12 months

Follow-up visits at 2, 4, 8, and 12 months

Treatment Details

Interventions

CUE-101 (Cancer Vaccine)

Trial OverviewThe trial is testing three different schedules of CUE-101 given before standard cancer treatments to see how safe it is and if it shows signs of working against the cancer. CUE-101 will be administered during the neoadjuvant phase, which means before main treatment starts. Researchers will collect blood and tumor samples to look for changes after giving CUE-101.

Participant Groups

3Treatment groups

Experimental Treatment

Group I: Schedule C: CUE-101Experimental Treatment1 Intervention

* In Schedule C, CUE-101 will be administered during the neoadjuvant phase as a single dose given 7 days prior to initiation of standard of care (SOC) therapy. * Standard of care therapy consists of surgery and postoperative adjuvant (cisplatin) and radiation therapy or cisplatin and radiation therapy (definitive-chemoradiation therapy)

Group II: Schedule B: CUE-101Experimental Treatment1 Intervention

* In Schedule B, CUE-101 will be administered during the neoadjuvant phase as two doses: one dose given 14 days and one dose given 7 days prior to initiation of standard of care (SOC) therapy. * Standard of care therapy consists of surgery and postoperative adjuvant (cisplatin) and radiation therapy or cisplatin and radiation therapy (definitive-chemoradiation therapy)

Group III: Schedule A: CUE-101Experimental Treatment1 Intervention

* In Schedule A, CUE-101 will be administered during the neoadjuvant phase as a single dose given 14 days prior to initiation of standard of care (SOC) therapy. * Standard of care therapy consists of surgery and postoperative adjuvant (cisplatin) and radiation therapy or cisplatin and radiation therapy (definitive-chemoradiation therapy)